Department of Gastroenterology, Faculty of Medicine, University of Tokyo, Tokyo, Japan.
Oncology. 2009;77(5):300-3. doi: 10.1159/000259616. Epub 2009 Nov 17.
We performed a pilot study of a modified combination chemotherapy regimen with S-1 plus gemcitabine for patients with advanced pancreatic cancer.
Gemcitabine was administered at a dose of 1,000 mg/m(2) in a 30-min intravenous injection on days 1 and 15. S-1 was administered orally at a dose of 40 mg/m(2) twice daily for 14 consecutive days followed by a 14-day rest. Each cycle was repeated every 28 days.
Sixteen patients were enrolled. No complete response was observed and partial response was observed in 5 patients (31.3%), stable disease in 10 patients (62.5%) and progressive disease in 1 patient (6.3%). The median time to progression was 10.0 months (95% CI 4.4-N.A.) and the median survival time was 20.4 months (95% CI 8.6-24.1 months). The major toxicities were grade 3 neutropenia (25.0%) and grade 3 anemia (6.3%). There were no grade 4 toxicities.
Combination therapy with gemcitabine and S-1 using the modified 4-week schedule was well tolerated and efficacious for advanced pancreatic cancer.
我们对晚期胰腺癌患者进行了 S-1 联合吉西他滨改良联合化疗方案的初步研究。
吉西他滨剂量为 1000mg/m2，静脉滴注 30 分钟，第 1 天和第 15 天给药。S-1 剂量为 40mg/m2，每日 2 次口服，连用 14 天，然后休息 14 天。每 28 天重复一个周期。
共纳入 16 例患者。无完全缓解，部分缓解 5 例（31.3%），稳定疾病 10 例（62.5%），进展疾病 1 例（6.3%）。中位无进展时间为 10.0 个月（95%CI 4.4-N.A.），中位总生存期为 20.4 个月（95%CI 8.6-24.1 个月）。主要毒性为 3 级中性粒细胞减少（25.0%）和 3 级贫血（6.3%）。无 4 级毒性。
吉西他滨联合 S-1 的改良 4 周方案治疗晚期胰腺癌耐受性良好，疗效确切。
